Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Novo Inibidor de Indenoisoquinolona CMYC/TOPOISOMERASE 1 (LMP744) em Glioblastoma Recorrente

15 de outubro de 2026 atualizado por: National Institute of Neurological Disorders and Stroke (NINDS)

Ensaio de Fase 1/Fase 2 de Etiqueta Aberta de um Novo Inibidor de C-MYC/TOPOISOMERASE 1 do Tipo Indenoisoquinolona (LMP744) em Glioblastoma Recorrente

Background:

Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal. Researchers want to know if a study drug (LMP744) can kill glioblastoma tumor cells.

Objective:

To test LMP744 in people with glioblastoma.

Eligibility:

People aged 18 years or older with glioblastoma that returned after treatment.

Design:

Participants will be screened. They will have a surgery to remove a small sample of tumor tissue (biopsy) from the brain. This will be done under protocol 03-N-0164. They will stay in the clinic for 1 night. They will also have imaging scans and tests of their heart function.

Participants will have a central line installed: A flexible tube will be inserted into a vein in the chest. It will be attached to a "port" under the skin. This port will be used to draw blood and give medicines without having to insert new needles into a vein.

LMP744 will be given through the central line for 5 days in a row. Participants will remain in the clinic for this time.

Participants will then have a second surgery to remove as much of their tumor as possible. They will remain in the clinic until they recover from the surgery. Then they will recover at home after surgery.

Participants will return to the clinic to receive the study drug for 5 days in a row through the central line, once a month for up to 12 months. Blood tests, heart function tests, and periodic imaging scans will be repeated during these visits.

Participants will continue to have telehealth visits every 3 months after they stop taking the drug.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

Study Description:

Patients will undergo pathological confirmation of recurrent glioblastoma via stereotactic or open biopsy (Visit 1, Day 1) to obtain baseline reference tissue. Following confirmation of recurrent glioblastoma by histopathological tissue analysis by a pathologist, study participants with confirmed histopathologically recurrent glioblastoma will be readmitted (Visit 2, Day 1). Patients will receive an initial cycle of 190 mg/m^2/day LMP744 infused over 1 hour for 5 consecutive days (Visit 2, Days 1-5). Participants will then undergo surgical intervention for brain biopsy and/or resection, as clinically appropriate based on neurosurgical assessment within 7 calendar days of the 5th dose of LMP744, but no earlier than 24 hours after the 5th dose of LMP744 (Visit 2, between Days 6 and 12 inclusive). Tissue, CSF, and plasma will be collected during the post-treatment surgical intervention for molecular analysis. Patients will then be discharged from the hospital. Following a 3-8-week period of recuperation, study participants will then resume LMP744 (5 days on; 23 days off; up to 12 cycles) and be followed until death.

A comparative pharmacodynamic analysis will be conducted on the pre- and post-treatment tissue to evaluate the biological response to LMP744 and correlate pharmacodynamic changes with clinical outcomes.

Objectives:

Primary Objective:

-To evaluate objective response rate (ORR) in patients with recurrent glioblastoma treated with up to 12 cycles of LMP744.

Secondary Objectives:

  • To evaluate progression-free survival in patients with recurrent glioblastoma treated with up to 12 cycles of LMP744 compared to historical controls.
  • To evaluate overall survival (OS) in patients with recurrent glioblastoma treated with up to 12 cycles of LMP744 compared to historical controls.
  • To assess the pharmacologic (PK/PD) response by exploring molecular and metabolic changes in pre- versus posttreatment glioblastoma tissue following administration of LMP744.
  • To assess the impact of LMP744 treatment on self-reported quality of life (QOL) as measured by the validated SF-36 instrument.

Exploratory Objective:

  • To explore the molecular changes observed in post-treatment tissue with clinical outcomes, aiming to identify potential predictive markers of response to LMP744.
  • To explore changes in the molecular and metabolic profiles in matched tissue, CSF, and plasma from patients treated with LMP744 compared to their pre-treatment baseline.

Safety Outcomes:

To descriptively monitor, document, and report adverse events (AEs) and serious adverse events (SAEs) in participants with recurrent glioblastoma treated with LMP744.

Endpoints:

Primary Endpoint:

-Stable disease or Partial response (>=50% disease reduction) or complete response (100% disease reduction) based on RANO 2.0 criteria

Secondary Endpoints:

  • PFS will be assessed based on the RANO 2.0 criteria for glioblastoma assessment as follows:

    • Imaging Criteria:

      • >=25% or more increase in enhancing lesions despite stable or increasing steroid dose
      • >=25% increase in non-enhancing FLAIR/T2W lesions, not attributable to other non-tumor causes
      • Occurrence of any new lesions

    • Clinical Features:

      • Clinical deterioration not attributable to other non-tumor causes or steroid decrease

  • Overall survival in patients treated with LMP744

  • Pharmacologic (PK/PD) response measured by molecular (transcriptomic, proteomic and/or metabolomic) tissue level changes and Differential molecular changes in tissues pre-versus post-LMP744 treatment

  • Self-reported quality of life (QOL) as measured by the SF-36 survey at baseline, after each treatment cycle, and at study completion.

Tipo de estudo

Intervencional

Inscrição (Estimado)

40

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

  • Estados Unidos
    • Maryland
      • Bethesda, Maryland, Estados Unidos, 20892
        • Recrutamento
        • National Institutes of Health Clinical Center
        • Contato:
        • Contato:
          • NIH Clinical Center Office of Patient Recruitment (OPR)
          • Número de telefone: TTY dial 711 800-411-1222
          • E-mail: ccopr@nih.gov

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 99 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

  • INCLUSION CRITERIA:

Participant must meet all the following inclusion criteria to be deemed eligible for this study:

  • Participants >= 18 years of age

  • Tissue-based diagnosis of recurrent glioblastoma, IDH-wildtype by a neuropathologist

  • Karnofsky Performance Status (KPS) >60

  • Willing to use effective birth control method

    --The effects of LMP744 on developing human fetuses are unknown. Therefore, females of childbearing potential and their male partners must be willing to use an effective method of contraception during the clinical study (hormonal, barrier, surgical, or abstinence) before study enrollment and for 6 months after the last dose of the study drug. If the female becomes pregnant or suspects she is pregnant while participating in this study, she must inform her treating physician immediately.

  • Agreeable to undergo surgical intervention for brain biopsy and/or resection.

    • Initial diagnostic biopsy under 03-N-0164 will be performed to confirm recurrent disease and obtain pre-treatment tissue.
    • The surgical intervention may include stereotactic/needle biopsy, open biopsy, and/or resection, as determined by neurosurgical assessment. Only participants for whom gross total resection of tumor is not expected to be achievable will be included in the study.

  • Willing and able to appoint a durable power of attorney

  • Able to provide informed consent or have a legally authorized representative (LAR) to provide consent, if incapacitated.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Pregnant and/or nursing females

    --As LMP744 is a novel agent with the potential for teratogenic or abortifacient effects, pregnant and/or nursing females will be excluded from receiving drug

  • Significant medical co-morbidities that would compromise the participant s ability to tolerate LMP744 and which cannot reasonably be controlled (per the investigator s judgment, such as poorly controlled chronic kidney disease and/or poorly controlled congestive heart failure)

  • Social situations that would limit compliance with study requirements, such as chronic homelessness

  • Prior chemotherapy or biologic therapy completed within 4 weeks (6 weeks for nitrosoureas and mitomycin C) or a duration of 5 half-lives (whichever is shorter)

  • Additional malignancy diagnosed or requiring active treatment within 1 year of screening

  • Unable to undergo an MRI scan of the brain

  • Active autoimmune disease that requires systemic treatment within 2 years of screening

  • Cardiac disease

    • >=2 MIs
    • >=2 coronary revascularization procedures
    • Cardiac Troponin T or I >= 2x the institutional upper limit of normal at screening
    • Ejection fraction <45% on screening echocardiogram

  • Chronic hypokalemia (K<2.5 mmol/L)

  • Human Immunodeficiency Virus (HIV)

    • Known history of HIV
    • Positive HIV 1/2 at screening.

  • Active Hepatitis B or Hepatitis C infection at screening

  • Active infection requiring systemic antibacterial, antiviral or antifungal therapy <7 days prior to initiation of study drug

  • Recipient of autologous or allogeneic T cells

  • Solid organ or tissue transplant recipients

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Arm A

All patients will receive LMP744 as the interventional drug along with surgery for a biopsy and a second surgery for either resection or an additional biopsy to compare the tissue pre vs. post-drug treatment.
Medicamento: LMP744

Indenoisoquinolone C-MYC/TOPOISOMERASE 1 Inhibitor

Procedimento: Conventional Surgery or Biopsy

Conventional Surgery or Biopsy

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Partial response (>=50% disease reduction) or complete response (100% disease reduction) based on RANO 2.0 criteria
Prazo: 5 years

As ORR is associated with survival experience, this endpoint allows for objective evaluation of efficacy of LMP744 in this proof-of-concept phase 2 trial
5 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Progression-Free Survival (PFS): Time from the start of treatment with LMP744 until disease progression based on RANO 2.0 criteria
Prazo: 5 years

PFS provides a measure of treatment efficacy in delaying tumor progression. While the study is not powered to demonstrate superiority of LMP744 to concurrent controls, the study will compare LMP744 to historical controls to generate information for planning of a future phase 3 trial.
5 years
Overall Survival (OS): Time from the start of treatment with LMP744 until death from any cause
Prazo: 5 years

OS is the gold standard for assessing the ultimate benefit of a therapy on survival. We will compare OS between LMP744 and historical controls to provide information for planning of a future phase 3 trial
5 years
Changes in transcriptomic and proteomic profiles before and after LMP744 treatment
Prazo: 5 years

Evaluating changes in these markers will provide insight into the pharmacodynamic effects of LMP744 at the molecular level. The selected markers are involved in DNA damage response, cell cycle regulation, and survival pathways, which are critical in understanding the tumor's response to the drug.
5 years
Change in self-reported quality of life (QOL) as measured by the SF-36 survey at baseline, after each treatment cycle, and at study completion.
Prazo: 5 years

The SF-36 is a validated tool for assessing the quality of life in cancer patients and captures the broad impact of treatment on physical, emotional, and social well-being. Tracking changes in QOL over time will provide insight into the patient-reported outcomes related to LMP744 treatment. This endpoint is essential for understanding the broader implications of treatment beyond clinical and molecular measures, giving a more comprehensive assessment of treatment benefit or burden.
5 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

National Institute of Neurological Disorders and Stroke (NINDS)

Investigadores

  • Investigador principal: Sadhana Jackson, M.D., National Institute of Neurological Disorders and Stroke (NINDS)

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Links úteis

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

15 de julho de 2026

Conclusão Primária (Estimado)

31 de dezembro de 2030

Conclusão do estudo (Estimado)

31 de dezembro de 2032

Datas de inscrição no estudo

Enviado pela primeira vez

14 de fevereiro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

17 de fevereiro de 2026

Primeira postagem (Real)

18 de fevereiro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de outubro de 2026

Última verificação

14 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 10002185
  • 002185-N

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

We plan to share IPD as requested by publications and CRADA partner.

Prazo de Compartilhamento de IPD

Study protocol will be shared as requested. CSR will be shared at the time the CSR is due.

Critérios de acesso de compartilhamento IPD

De-identified IPD will be shared with the CRADA partner through the EDC.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever